Abpro Holdings, Inc. ABPO
0.41 USD -0.04 (-9.94%)
Nov 3, 2026, 1:16 PM EST
0.405 Day range 0.46
0.087 52-week range 7.34
- YTD
- -90.43%
- 1 year
- -92.31%
News
defenseworld.net Short Interest in Abpro Holdings Inc. (NASDAQ:ABP) Increases By 271.4% Abpro Holdings Inc. (NASDAQ: ABP - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling…
globenewswire.com Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors,…
globenewswire.com Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 FDA clearance enables initiation of Abpro's first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro's global collaboration with…
defenseworld.net Abpro (NASDAQ:ABP) Stock Price Up 0.2% – Still a Buy? Shares of Abpro Holdings Inc. (NASDAQ: ABP - Get Free Report) were up 0.2% during trading on Thursday. The stock traded as high as $4.80 and last traded at $4.79. Approximately 12,770 shares changed…
globenewswire.com Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents…
globenewswire.com Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today…
globenewswire.com Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (Nasdaq: ABP) (“Abpro”) and Celltrion, Inc. (“Celltrion”) today announced that they will present new preclinical data for…
globenewswire.com Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune® platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq…
defenseworld.net Abpro Holdings Inc. (NASDAQ:ABP) Sees Large Decrease in Short Interest Abpro Holdings Inc. (NASDAQ: ABP - Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling…
globenewswire.com Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of…
globenewswire.com Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and…
globenewswire.com Abpro Statement on the Departure of Former CEO Ian Chan WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and…
globenewswire.com Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening…